What’s new in breast pathology 2022: WHO 5th edition and biomarker updates

The 5th edition WHO Classification of Breast Tumours (2019) has introduced changes to our practices. Highlights are presented below, with a focus on modifications to morphological subtype categorization. In addition, we summarize important updates to ER and PR testing made in the 2020 ASCO/CAP guide...

Descripción completa

Detalles Bibliográficos
Autores principales: Muller, Kristen, Jorns, Julie M., Tozbikian, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists and the Korean Society for Cytopathology 2022
Materias:
Newsletter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119809/
https://www.ncbi.nlm.nih.gov/pubmed/35581732
http://dx.doi.org/10.4132/jptm.2022.04.25
_version_ 1784710773008760832
author Muller, Kristen
Jorns, Julie M.
Tozbikian, Gary
author_facet Muller, Kristen
Jorns, Julie M.
Tozbikian, Gary
author_sort Muller, Kristen
collection PubMed
description The 5th edition WHO Classification of Breast Tumours (2019) has introduced changes to our practices. Highlights are presented below, with a focus on modifications to morphological subtype categorization. In addition, we summarize important updates to ER and PR testing made in the 2020 ASCO/CAP guidelines, and briefly discuss PD-L1 and Ki-67 testing in breast cancer.
format Online
Article
Text
id pubmed-9119809
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Pathologists and the Korean Society for Cytopathology
record_format MEDLINE/PubMed
spelling pubmed-91198092022-05-27 What’s new in breast pathology 2022: WHO 5th edition and biomarker updates Muller, Kristen Jorns, Julie M. Tozbikian, Gary J Pathol Transl Med Newsletter The 5th edition WHO Classification of Breast Tumours (2019) has introduced changes to our practices. Highlights are presented below, with a focus on modifications to morphological subtype categorization. In addition, we summarize important updates to ER and PR testing made in the 2020 ASCO/CAP guidelines, and briefly discuss PD-L1 and Ki-67 testing in breast cancer. The Korean Society of Pathologists and the Korean Society for Cytopathology 2022-05 2022-05-15 /pmc/articles/PMC9119809/ /pubmed/35581732 http://dx.doi.org/10.4132/jptm.2022.04.25 Text en © 2022 The Korean Society of Pathologists/The Korean Society for Cytopathology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Newsletter
Muller, Kristen
Jorns, Julie M.
Tozbikian, Gary
What’s new in breast pathology 2022: WHO 5th edition and biomarker updates
title What’s new in breast pathology 2022: WHO 5th edition and biomarker updates
title_full What’s new in breast pathology 2022: WHO 5th edition and biomarker updates
title_fullStr What’s new in breast pathology 2022: WHO 5th edition and biomarker updates
title_full_unstemmed What’s new in breast pathology 2022: WHO 5th edition and biomarker updates
title_short What’s new in breast pathology 2022: WHO 5th edition and biomarker updates
title_sort what’s new in breast pathology 2022: who 5th edition and biomarker updates
topic Newsletter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119809/
https://www.ncbi.nlm.nih.gov/pubmed/35581732
http://dx.doi.org/10.4132/jptm.2022.04.25
work_keys_str_mv AT mullerkristen whatsnewinbreastpathology2022who5theditionandbiomarkerupdates
AT jornsjuliem whatsnewinbreastpathology2022who5theditionandbiomarkerupdates
AT tozbikiangary whatsnewinbreastpathology2022who5theditionandbiomarkerupdates

Ejemplares similares